CION Ameerpet
Prevention Guide · Reviewed by CION Oncologists · NABH Accredited
Types of HPV Vaccine — Bivalent, Quadrivalent and Nonavalent
There is only one HPV vaccine technology, but three families of formulation, and they differ in exactly one respect: how many HPV types they cover. A bivalent vaccine covers two, a quadrivalent covers four, and a nonavalent covers nine. Every one of them covers the two high-risk types responsible for most cervical cancer worldwide, which is why the choice is far less momentous than the price difference suggests. This guide sets out what each formulation includes, where the extra coverage actually matters, and how our oncologists across CION’s 7 NABH-accredited Hyderabad locations talk families through the decision.
- All three cover HPV 16 and 18 — the two types behind the majority of cervical cancers
- Quadrivalent and nonavalent add wart protection — bivalent formulations do not
- Doses depend on age, not formulation — the schedule is set by how old you are at dose one
- 45-minute consultation — with a woman doctor available on request, at every CION location
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What “Valency” Means, and Why It Is the Only Real Difference
There are more than 200 human papillomavirus types, of which around a dozen are classed as high-risk for cancer and two more are responsible for most genital warts. No vaccine can cover them all. Valency is simply the count of types a particular formulation targets — bi (two), quadri (four), nona (nine).
Underneath, the technology is identical across all of them. Each vaccine is made of virus-like particles: empty shells assembled from the L1 surface protein of the virus, carrying no viral DNA whatsoever. Your immune system sees the shape, learns to neutralise it, and remembers. Nothing in any of these formulations can cause an HPV infection, and none of them contains a live or weakened virus. If you want the mechanism in full, it is set out on our HPV vaccine overview.
Because the platform is shared, the practical differences between formulations come down to three things, and only three:
- How many cancer-causing types are covered — two, or seven in the nonavalent formulation.
- Whether genital wart types are included — quadrivalent and nonavalent include them, bivalent does not.
- What it costs and whether it is in stock — which, in India, is frequently the deciding factor. See HPV vaccine cost in Hyderabad.
What does not vary by formulation is the number of doses. That is set by the age at which the first dose is given, as explained on our dose and schedule page.
Did You Know? Just two HPV types — 16 and 18 — are responsible for roughly seven in ten cervical cancers worldwide, and a nonavalent formulation’s seven high-risk types together account for around nine in ten. That is why even the simplest bivalent vaccine removes most of the risk, and why the extra valency is an improvement rather than a different order of protection. Sources: WHO position paper on human papillomavirus vaccines; IARC Monographs on Biological Agents.
The Three Formulations, Side by Side
Availability changes from year to year and clinic to clinic, so ask what is actually in stock before settling on a preference. All licensed formulations in India are approved by the national regulator and given the same way.
Two types
Bivalent
Targets HPV 16 and 18 only — the two types behind most cervical cancer. It does not cover the low-risk types that cause genital warts. Straightforward, well studied over many years, and typically the least expensive option where it is stocked.
Four types
Quadrivalent
Covers HPV 16 and 18 for cancer, plus the two low-risk types responsible for the great majority of genital warts. For years this was the workhorse formulation worldwide, and an Indian-manufactured quadrivalent vaccine has made it considerably more affordable here.
Nine types
Nonavalent
Everything the quadrivalent covers, plus five additional high-risk types — 31, 33, 45, 52 and 58. It offers the widest protection available and is usually the most expensive. Where budget allows, it is the formulation most clinicians will suggest first.
Shared by all
Same Technology, No Live Virus
Every formulation uses non-infectious virus-like particles. None can give you HPV, none contains viral DNA, and all are given as an injection into the upper arm with the same short observation period afterwards.
Shared by all
Same Dose Rules
Two doses when the course starts before the fifteenth birthday, three doses when it starts at 15 or later, and three doses for people who are immunosuppressed — regardless of which formulation is used.
Shared by all
Screening Still Applies
No formulation covers every high-risk type, so cervical screening continues on the recommended schedule for every vaccinated woman. Vaccination narrows the risk; screening catches what is left.
We deliberately do not name products on this page. Which brand is stocked, at what price, and in what strength is a question for the clinician who will actually give the injection.
How the Choice Is Actually Made in Clinic
WHO’s position is that the licensed HPV vaccines have comparable efficacy against HPV 16 and 18, and that programmes should choose on the basis of the local disease burden, price and availability rather than on a claim that one product is categorically superior. That is a useful principle for an individual family too.
If the budget stretches, wider coverage is the better buy
The five extra high-risk types in the nonavalent formulation are not rare. Adding them takes the covered share of cervical cancers from roughly seven in ten to around nine in ten, and that difference lasts a lifetime for a child being vaccinated now. If a family is choosing once and paying once, this is the formulation to ask about first.
If it does not, the vaccine you can complete beats the one you cannot
A completed two-dose course of a cheaper formulation protects far better than an abandoned course of an expensive one. The most common failure we see is not the wrong product — it is a second or third dose never given. Cost matters precisely because it determines whether the course finishes.
If genital warts are a specific concern, bivalent is not the one
Warts are not a cancer risk, but they are common, distressing and awkward to treat. Only the quadrivalent and nonavalent formulations include the low-risk types that cause most of them — a point worth raising for boys as well as girls.
A note on what none of these vaccines do: they prevent infection, they do not treat it. No formulation will clear an HPV infection you already carry or reverse an abnormal smear, and none of them treats cancer. If a diagnosis has already been made, the relevant page is cervical cancer treatment in Hyderabad, and the wider picture is on the cervical cancer overview.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
The Right Vaccine Is the One That Gets Completed
Bring your questions about coverage, cost and timing to one 45-minute consultation and leave with a written schedule. A woman doctor is available on request at every CION location.
Coverage Compared, Line by Line
Read this as a coverage table, not a ranking. The bottom two rows are identical for every formulation, and they matter more than the rows above them.
| Bivalent | Quadrivalent | Nonavalent | |
|---|---|---|---|
| High-risk types covered | HPV 16, 18 | HPV 16, 18 | HPV 16, 18, 31, 33, 45, 52, 58 |
| Low-risk (wart) types covered | None | Two | Two |
| Share of cervical cancers targeted | About 70% | About 70% | About 90% |
| Prevents genital warts | No | Yes | Yes |
| Typical relative cost in India | Lower | Lower to mid | Highest |
| Doses required | Set by age at first dose — two doses under 15, three doses from 15 onwards, three if immunosuppressed | ||
| Screening still needed afterwards | Yes, for every woman, on the recommended schedule — no formulation covers every high-risk type | ||
Percentages describe the share of cervical cancers attributable to the covered types worldwide, not the efficacy of any individual product. Source: WHO position paper on human papillomavirus vaccines.
Switching, Mixing and Topping Up
These three questions come up constantly at the counter, and the answers are more relaxed than most people expect.
Starting with one formulation and finishing with another
Completing the course with the same formulation you started with is preferred, because that is how the schedules were studied. But if the original product is unavailable or its identity is unknown, guidance is that the course should be completed with whatever suitable formulation is at hand rather than abandoned or restarted from the beginning. Finishing matters more than consistency.
Adding a wider-coverage vaccine after an earlier course
Someone who had a bivalent or quadrivalent course years ago is already protected against the two types that matter most. Taking a further nonavalent course adds coverage of five more high-risk types, and it is safe, but the additional benefit is modest and it is a full extra course at full cost. This is a reasonable thing to want and an entirely optional thing to do — a decision to make with a doctor, on your own circumstances, not a gap that needs urgent filling.
An interrupted schedule
A delayed second or third dose is not a failed course. There is no need to restart; the remaining doses are simply given, respecting the minimum intervals. If a dose has been missed for months or years, book the next one rather than writing the whole thing off.
What the choice cannot buy you
No formulation removes the need for cervical screening, and none of them protects against types outside its own list. A woman who has had the widest available vaccine still needs her Pap smear or HPV test on schedule — a point NCCN, ESMO and WHO screening guidance all make explicitly.
Did You Know? In 2022 WHO’s Strategic Advisory Group of Experts on Immunization concluded that a single-dose HPV schedule delivers comparable protection to two doses in girls aged 9 to 14, and several national programmes have since adopted it to widen coverage. It applies across the licensed formulations — further evidence that the schedule, not the brand, is the variable that has been studied hardest. Source: WHO SAGE recommendations on HPV vaccine schedules.
Why Families in Hyderabad Ask CION Before Buying
A vaccine decision made at a pharmacy counter is made on price and stock. Made with an oncologist, it is made on risk.
Advice from cancer specialists
No product pushing
Whole-family planning in one visit
45-minute detailed consultation
Woman doctor available on request
Screening arranged alongside
7 NABH-accredited Hyderabad locations
Transparent, itemised costs
4.8 / 5 Google rating
Take The Next Step
Decide Once, Then Get It Done
Comparing formulations for weeks costs more protection than choosing the second-best one today. Book the consultation, agree the schedule, and start.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Types of HPV Vaccine — Frequently Asked Questions
Is the nonavalent vaccine worth paying more for than the quadrivalent?
If the budget allows, yes — and if it does not, the difference is smaller than the price gap suggests. Both cover the two HPV types responsible for roughly seven in ten cervical cancers, and both cover the low-risk types that cause most genital warts. The nonavalent formulation adds five further high-risk types, taking the covered share of cervical cancers to around nine in ten. For a child being vaccinated once, that broader cover lasts a lifetime and is worth asking about first. For a family choosing between a completed cheaper course and an unaffordable wider one, the completed course wins every time.
I had the quadrivalent vaccine years ago. Should I now take the nonavalent one?
It is safe to do so, and it would add protection against five additional high-risk types. But you are already covered against the two types that account for most cervical cancer, so the incremental gain is modest and it means a complete extra course at full cost. There is no guideline that requires it. Treat it as an optional upgrade to discuss with your doctor based on your age and circumstances, not as a gap in your protection that needs urgent filling. What is not optional is continuing cervical screening on the recommended schedule.
Can I start with one HPV vaccine and finish the course with a different one?
Completing the course with the same formulation is preferred, because that is how the schedules were tested. However, if the original product is out of stock or you cannot find out which one you were given, guidance is clear that the course should be completed with an available suitable formulation rather than abandoned or restarted from dose one. An interrupted schedule does not need to begin again either — the remaining doses are simply given, respecting the minimum intervals. See the dose schedule in detail.
Does the bivalent vaccine protect against genital warts?
No. Genital warts are caused mainly by two low-risk HPV types that are not associated with cancer, and the bivalent formulation does not include them — it targets only the two high-risk cancer-causing types. Quadrivalent and nonavalent formulations do include them, and where warts are a specific worry that is a legitimate reason to prefer one of those. It is worth raising for boys as well as girls, since warts affect both and are unpleasant to treat regardless of gender.
Is an Indian-made HPV vaccine as good as an imported one?
Formulations manufactured in India are licensed by the national regulator against the same standards applied to imported products, and an Indian-made quadrivalent vaccine has substantially reduced the cost of protecting a child here. What matters clinically is the valency — how many HPV types the formulation covers — and the age at which the course is started, not where the vial was filled. Ask your clinician what is in stock, what valency it is, and what the full course will cost, and compare on those three facts. See current cost guidance for Hyderabad.
Medical disclaimer: This page is general health information, reviewed by a CION oncologist. It is not a prescription and cannot replace a consultation. This page describes HPV vaccine formulations by valency only and does not recommend any product. Which vaccine is appropriate for you, and how many doses you need, must be decided by a qualified doctor who knows your age and medical history.